Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

NCT02841150 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: IMBRUVICA (Treatment A)
DRUG: Ibrutinib (Treatment B)

Sponsor

Janssen Research & Development, LLC